Sun Pharma gets US nod for leukaemia drug
November 17th, 2009 - 12:09 pm ICT by IANS ( Leave a comment )Mumbai, Nov 17 (IANS) Indian drug major Sun Pharmaceuticals Tuesday said it has secured tentative approval from the United States Food and Drugs Administration for the generic version of Gleeven, used to treat chronic myeloid leukaemia.
The drug will be available in two strengths of 100 mg and 400 mg and the market size for them is estimated at nearly $900 million, the pharmaceuticals company said in a filing with the stock exchanges.
The shares of the company were, however, down Rs.13.75, or 0.93 percent, at the Bombay Stock Exchange, and were ruling at Rs.1,463.90 some half-hour into the trading session Monday.
- Ranbaxy approved to make first generic version of Lipitor - Dec 01, 2011
- Orchid gets tentative FDA approval for Alzheimer's drug - Jan 08, 2010
- HDFC quarterly net profit up 20 percent - Oct 17, 2011
- Dr. Reddy's reports 37 percent jump in profit for 2nd quarter - Oct 23, 2010
- Abbott to buy Piramal's branded drugs business for $3.71 bn (Roundup) - May 21, 2010
- Piramal concludes sale of formulations business to Abott - Sep 08, 2010
- Abbott to buy Piramal's branded drugs business for $3.71 bn (Lead) - May 21, 2010
- Ranbaxy gets USFDAs permission to manufacture cardiovascular drugs - Mar 09, 2009
- Leukaemia vaccine goes on clinical trial - Feb 01, 2011
- Surya Pharma's arm acquires US's ActivOn for $22 mn - Dec 28, 2010
- Indian drug major Sun Pharma takes control of Israeli Taro - Sep 22, 2010
- Omaxe bags Rs.127.93 crore contract from Defence Ministry - Sep 13, 2010
- Sensex closes 151 points lower as earnings disappoint (Roundup) - Jul 20, 2011
- Nirma shareholders vote for delisting - Nov 22, 2010
- Sensex rises in early trade - Nov 22, 2010
Tags: bombay stock exchange, drugs administration, generic version, half hour, myeloid leukaemia, pharmaceuticals company, rs 1, stock exchanges, sun pharma, sun pharmaceuticals, tentative approval, trading session
